CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 94,958	$ 24,039
Advance for COVAXIN supply	4,988	0
Prepaid expenses and other current assets	2,700	1,839
Total current assets	102,646	25,878
Property and equipment, net	1,164	633
Restricted cash	151	151
Other assets	1,800	714
Total assets	105,761	27,376
Current liabilities
Accounts payable	2,312	395
Accrued expenses and other current liabilities	4,325	2,941
Short-term debt, net	0	234
Operating lease obligations	363	44
Total current liabilities	7,000	3,614
Non-current liabilities
Operating lease obligations, less current portion	1,231	389
Long term debt, net	1,712	1,823
Total non-current liabilities	2,943	2,212
Total liabilities	9,943	5,826
Commitments and contingencies (Note 14)
Stockholders’ equity
Common stock; $0.01 par value; 295,000,000 and 200,000,000 authorized; 199,502,183 and 184,133,384 shares issued, and 199,380,683 and 184,011,884 shares outstanding at December 31, 2021 and 2020, respectively	1,995	1,841
Treasury Stock, at cost, 121,500 shares at December 31, 2021 and 2020	(48)	(48)
Additional paid-in capital	225,537	93,059
Accumulated deficit	(131,667)	(73,302)
Total stockholders’ equity	95,818	21,550
Total liabilities and stockholders’ equity	105,761	27,376
Series A Convertible Preferred Stock
Stockholders’ equity
Preferred stock issued	0	0
Series B Convertible Preferred Stock
Stockholders’ equity
Preferred stock issued	$ 1	$ 0